Distributions of the reported lifetime number of partners by country and sex.

<p>Distributions of the reported lifetime number of partners by country and sex.</p

Concurrency prevalence, overlap duration and coital frequency.

<p>*Too few observations to estimate.</p>1<p>Unweighted.</p>2<p>In the last year for Uganda and the US, in the last 6 months for Thailand; data for Thailand and US are collected in categories.</p>3<p>Median (75^th percentile).</p

Additional file 3: Table S3. of Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda

Risk factors of Immunologic decline, virologic increase or death among HIV infected adults failing on first line ART and switched to Second line ART. Cox proportional MSM model of the time to event of composite endpoint defined as reaching immunologic decline or virologic increase as defined in a and b above, or dying. (DOCX 16 kb

Additional file 2: Table S2. of Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda

Risk factors of virologic increase among HIV infected adults failing on first line ART and switched to Second line ART. Cox proportional MSM model of the time to event of virologic increase defined as increase in viral load ≥0.5 log 10 copies/ml above viral load at virologic failure. (DOCX 16 kb

50 Koska-Langa : Nişanca / Jak. Pervitiç

Échelle(s) : Échelle : 1/1000Numérisé par le partenaireAppartient à l’ensemble documentaire : BbLevt0Numérisé par le partenair

General characteristics of FGD participants (n = 92).

<p>F Female. M Male</p

General characteristics of in depth interviewees (IDIs) (n = 20).

<p>F Female. M Male</p